Drug intelligence / Profile preview

PA-41

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

PA-41 is an experimental humanized monoclonal antibody directed against Clostridioides difficile toxin B, developed as part of a toxin-directed antitoxin strategy for the prevention and treatment of C. difficile infection. It was generated to bind a novel neutralizing epitope on toxin B with high affinity, with the goal of blocking toxin-mediated cytotoxicity and intestinal inflammation, and has been investigated in combination with the companion antibody PA-50, which targets toxin A, as a dual-antitoxin antibody therapy.

Targets

GTD (Clostridioides difficile toxin glucosyltransferase domain)

Beyond the preview

Go deeper on PA-41.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PA-41.

Explore the full profile